Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2022-12-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于股东通过司法程序取得的限售股份解除限售的提示性公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the unlocking (解除限售) of restricted shares previously held by a shareholder who acquired them through judicial procedures. It details the number of shares, the background of the shares, the shareholder's commitments, and the effective date of the shares becoming tradable. The document includes specific dates, share quantities, and references to board and supervisory meetings approving the unlocking. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor is it a call transcript or management discussion. The document is an official disclosure about a change in share status and shareholder rights, which fits the category of Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other more specific categories like Share Issue/Capital Change (SHA) because it concerns unlocking of restricted shares rather than new issuance or capital structure change. The document length is under 5,000 characters, and it is a standalone announcement rather than a report or presentation. Therefore, the best classification is Regulatory Filings (RNS).
2022-12-14 Chinese
独立董事候选人关于参加最近一次独立董事培训的书面承诺
Regulatory Filings Classification · 95% confidence The document is a brief announcement regarding an independent director candidate's written commitment to attend training and obtain a qualification certificate recognized by the Shenzhen Stock Exchange. It does not contain financial data, report content, or detailed management or governance information. It is a short notice about a director candidate's status and commitment, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement without fitting into more specific categories.
2022-12-04 Chinese
独立董事候选人声明（姜明辉）
Board/Management Information Classification · 95% confidence The document is a public statement by an independent director candidate of Harbin Yuheng Pharmaceutical Co., Ltd. It contains detailed declarations about the candidate's qualifications, independence, compliance with relevant laws and regulations, and absence of conflicts of interest. There is no financial data, no discussion of company financial performance, no voting results, no management changes, and no mention of any report publication. The document is a formal declaration related to board/management information, specifically concerning the appointment and qualifications of an independent director candidate. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4993 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive declaration related to management.
2022-12-04 Chinese
独立董事候选人声明（潘敏）
Board/Management Information Classification · 95% confidence The document is a public statement by an independent director candidate of Harbin Yuheng Pharmaceutical Co., Ltd. It contains declarations about the candidate's qualifications, independence, compliance with relevant laws and regulations, and absence of conflicts of interest. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal declaration related to board/management information, specifically about an independent director candidate's qualifications and compliance. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is about 5090 characters, which is consistent with a detailed declaration rather than a brief announcement or a full report.
2022-12-04 Chinese
关于召开2022年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a notice about convening the 2022 second extraordinary general meeting of shareholders for Harbin Gloria Pharmaceuticals Co., Ltd. It details the meeting time, location, agenda items (such as election of independent directors), voting procedures including cumulative voting, registration methods, and proxy forms. There is no financial data or results reported, nor is it a transcript or presentation. It is an official announcement informing shareholders about the meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to provide information and request votes for meetings.
2022-12-04 Chinese
独立董事关于第六届董事会第一次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an announcement from independent directors regarding the nomination of independent director candidates for the company's sixth board meeting. It discusses compliance with relevant laws, qualifications of nominees, and the board meeting procedures. There is no financial data, no mention of annual or interim reports, earnings, or other financial disclosures. The content focuses on board/management information related to director nominations and approvals. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2022-12-04 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.